Pharmacist Warns Against Buying Retatrutide Online as UK Searches Surge 658%

A pharmacist is urging people not to buy or inject products claiming to contain retatrutide after UK searches for the experimental weight-loss drug increased by 658% in a year.

Analysis by online pharmacy Curely found an estimated 155,000 searches for “retatrutide” were made in the UK during the most recent month.

Interest in the drug was negligible until 2024, according to the five-year search trend, but began growing during 2025 before accelerating sharply throughout 2026.

Retatrutide is being developed by pharmaceutical company Eli Lilly and has produced significant weight-loss results in a Phase 3 clinical trial. However, it remains an investigational medicine and has not been authorised for medicinal use in the UK.

The Medicines and Healthcare products Regulatory Agency has explicitly warned consumers not to be tempted by online hype surrounding retatrutide. It says anyone currently selling it as a medicine in the UK is doing so illegally and that such products have not been assessed for safety, quality or effectiveness. (MHRA)

Pharmacist’s Advice: Do Not Buy Retatrutide Online

Sobia Qasim, pharmacy expert at Curely, said the rapid growth in public interest could create an opportunity for unregulated sellers to exploit people who want to access the drug before it is approved.

She said:

“A 658% increase in searches shows just how quickly awareness of retatrutide is spreading in the UK.

“The concern is that people aren’t only reading about what could become a future weight-loss treatment. Some will inevitably be searching for ways to access it now.

“Retatrutide is still an investigational medicine. It has not been authorised for medicinal use in the UK, so people should be extremely wary of any website, social media account or online seller claiming they can currently provide it as a weight-loss treatment.”

Her advice is clear: people should not purchase or use any product advertised as retatrutide outside an authorised clinical trial.

Unlike an approved prescription medicine supplied by a registered pharmacy, an illegally sold injectable may not have undergone appropriate manufacturing, quality-control, sterility or storage checks.

Consumers should also be cautious about products advertised through social media, messaging groups, beauty businesses or websites that do not require a valid prescription.

What Is Retatrutide?

Retatrutide is an experimental, once-weekly medicine described as a “triple agonist”.

It activates three hormone receptors – GIP, GLP-1 and glucagon – involved in areas including appetite, metabolism and blood-sugar regulation.

This differs from tirzepatide, the active ingredient in Mounjaro, which acts on GIP and GLP-1 receptors.

Public interest in retatrutide has been fuelled by results from Eli Lilly’s TRIUMPH-1 Phase 3 obesity trial.

Participants receiving the highest 12mg dose lost an average of 28.3% of their body weight over 80 weeks. Among participants who began with a BMI of at least 35 and continued into an extension of the trial, average weight loss reached 30.3% after 104 weeks. (Eli Lilly: TRIUMPH-1 Phase 3 results)

However, clinical trial results should not be interpreted as proof that a medicine is ready or authorised for general use.

Qasim said:

“There is a huge difference between a medicine producing promising results in a controlled clinical trial and that medicine being approved for routine treatment.

“Clinical trials exist precisely because researchers still need to establish the medicine’s safety, effectiveness, dosing and wider risk-benefit profile.

“People shouldn’t see a headline saying participants lost around 28% of their body weight and assume the next step is to find somewhere online selling it.”

“You May Have No Idea What You’re Actually Injecting”

Products advertised as retatrutide are already being offered through illicit and grey-market suppliers, despite the drug remaining unapproved.

Eli Lilly says no medicine containing retatrutide has been approved for human use by any regulatory agency anywhere in the world. The company has taken legal action against businesses accused of selling black-market products purporting to contain the drug. (Eli Lilly: action against illegal retatrutide sellers)

The MHRA has previously seized unauthorised weight-loss products, including substances advertised as retatrutide, from suspected illegal manufacturing and distribution operations in the UK.

Qasim warned that consumers could not rely on labels, packaging or claims made by sellers.

“If you’re buying an unapproved injection through an illegal or unregulated source, you may have no reliable guarantee of what is actually inside that vial.

“There are questions around the identity and strength of the substance, sterility, contamination, manufacturing standards, storage and transportation.

“A professional-looking website, packaging or testimonial on social media does not prove that an injectable product has been manufactured to the standards required of an authorised medicine.”

An injectable product made or handled without proper controls could contain the wrong ingredient, an inaccurate dose or harmful contamination. It may also have been stored or transported at an unsuitable temperature.

Consumers cannot determine whether an injectable is sterile simply by looking at the liquid, vial or packaging.

The MHRA similarly warns that illegally supplied medicines may not contain what they claim and may not have been manufactured, transported or stored to the standards required of an authorised product. (UK warning over unlicensed retatrutide sales)

Do Not Stop Prescribed Treatment Because of Retatrutide Headlines

The trial results have prompted comparisons between retatrutide and authorised weight-management medicines such as Mounjaro.

However, a larger average weight-loss percentage in one clinical trial does not automatically make a drug the most appropriate treatment for every patient.

People already taking prescribed weight-management medication should not stop, reduce or change their treatment after reading about retatrutide. Any concerns about progress, side effects or dosing should be discussed with the patient’s prescriber or pharmacist.

Qasim said:

“Weight-loss medicines shouldn’t be treated like a league table where whichever drug produces the biggest percentage automatically becomes the best option.

“Someone doing well on an existing prescribed treatment shouldn’t abandon it because they’ve read about a new medicine producing greater average weight loss in a trial.

“Treatment decisions need to consider the individual, including their medical history, response to treatment, side effects, other medications and overall health.

“If someone feels their current weight-loss medication isn’t working as expected, the right conversation is with their prescriber, not an unregulated seller offering an experimental alternative.”

An authorised medicine is prescribed after a healthcare professional assesses whether it is appropriate for the individual. That assessment may consider BMI, existing medical conditions, current medication and the risk of potential side effects.

Medical supervision also provides an opportunity to monitor progress and respond if a patient experiences problems.

“Research Use Only” Is a Warning, Not a Loophole

Some online products are labelled “research use only” or “not for human consumption”.

These phrases do not mean a product is an unofficial, early or generic version of an approved medicine. They indicate that it has not been supplied as a treatment authorised for use by patients.

Eli Lilly states that retatrutide is available only to eligible participants enrolled in its clinical trials and warns people not to take products claiming to contain the drug outside those studies. (Eli Lilly: what to know about retatrutide)

Qasim said:

“The words ‘research use only’ do not mean you’ve found an unofficial early version of an approved medicine.

“If something is not authorised for human use, consumers shouldn’t be attempting to use it on themselves simply because it’s available to purchase online.

“The excitement around retatrutide is understandable, particularly given the trial results we’re seeing. But waiting for the regulatory process matters.

“The fact that UK searches have risen 658% shows there is already enormous curiosity around this drug. That makes clear, responsible information particularly important before online demand moves even further ahead of regulation.”

What Should Consumers Do?

Anyone considering medication to support weight management should speak to a GP, pharmacist or another qualified prescriber.

Prescription medicines should only be obtained through a registered pharmacy following an appropriate clinical assessment and a valid prescription.

Consumers who encounter a website or social-media seller offering retatrutide can report a suspicious online medicines seller to the MHRA. Reports can be made anonymously.

Anyone who has already used a product sold as retatrutide and feels unwell should seek medical advice. NHS 111 can provide urgent guidance when a situation is not life-threatening, while serious or rapidly worsening symptoms require emergency help.

People should tell the healthcare professional exactly what they believe they used, how much they took, when they took it and where it came from. Keeping the packaging, vial and details of the seller may also help clinicians and regulators understand what has happened.

Sources

Curely

Eli Lilly: TRIUMPH-1 Phase 3 results

Eli Lilly: What to know about retatrutide

Eli Lilly: action against illegal retatrutide sellers

UK warning over unlicensed retatrutide sales

The Guardian: retatrutide grey market investigation

Search data source:, UK Google search data, accessed September 2026.